Tag: imfinzi durvalumab market size

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Imfinzi (durvalumab) Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The market for imfinzi (durvalumab) has seen rapid expansion in recent years. It is forecast to grow from $3.01 million in 2025 to $3.36 million in 2026, demonstrating a compound annual growth rate (CAGR) of 11.4%. Historically, this growth can be attributed to the clinical success of immune checkpoint inhibitors, the increasing prevalence of lung cancer, regulatory approvals in oncology, improved survival outcomes, and strong pharmaceutical investment.

The imfinzi (durvalumab) market is projected for substantial expansion over the coming years. This market is anticipated to reach $5.11 million by 2030, exhibiting a compound annual growth rate (CAGR) of 11.1%. Factors contributing to this projected growth include the extension into additional cancer indications, enhanced availability of immunotherapy, an increase in oncology clinical trials, escalating healthcare expenditure in oncology, and the creation of new combination treatment protocols. Key developments expected during this period encompass the increasing uptake of PD-L1 inhibitors, the wider application of immunotherapy in lung cancer, the proliferation of combined immuno-oncology treatments, a heightened emphasis on biomarker-guided therapies, and its expanded utility across various solid tumors.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=56788307&type=smp&name=Imfinzi%20%28durvalumab%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Imfinzi (durvalumab) Market Growth Backed By Core Demand Fundamentals

The rising occurrence of cancer is projected to propel the expansion of the Imfinzi (durvalumab) market. Cancer describes a collection of illnesses marked by the unrestrained multiplication and spread of abnormal cells within the body, which can infiltrate and harm normal tissues. This increase in cancer cases is largely attributed to an aging population, given that cancer risk rises with age, alongside lifestyle elements such as smoking, an unhealthy diet, and obesity, all contributing to higher cancer rates. Durvalumab (Imfinzi) functions in cancer treatment by suppressing the PD-L1 protein, preventing cancer cells from evading detection by the immune system. For example, the National Cancer Institute (NIH), a US-based government agency, reported in May 2024 that the U.S. had 18.1 million cancer survivors in 2022, a number anticipated to climb to 22.5 million by 2032. Hence, the increasing incidence of cancer is a key driver for the Imfinzi (durvalumab) market’s growth. The growing adoption of personalized medicine is expected to stimulate the expansion of the Imfinzi (durvalumab) market moving forward. Personalized medicine is a medical strategy that customizes treatment and healthcare plans to align with each patient’s individual characteristics, such as their genetic makeup, environment, and lifestyle, aiming for the most effective and precise outcomes. The rise of personalized medicine is fueled by progress in genomic technologies, an enhanced comprehension of molecular biology, the increasing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient results while minimizing side effects. Imfinzi (durvalumab) supports personalized medicine by targeting and inhibiting the PD-L1 protein, thereby enabling tailored immunotherapy treatments for cancer patients based on their specific tumor biology and immune system characteristics, which enhances treatment efficacy and reduces unnecessary side effects. For instance, according to the Personalized Medicine Coalition, a US-based representative organization, in 2023, the FDA approved personalized medicines for 34% of new drugs in 2022, and for at least 25% of new drugs during the previous eight years. Consequently, the advancement of personalized medicine is a significant driver for the Imfinzi (durvalumab) market.

Imfinzi (durvalumab) Market Segment Landscape And Growth Outlook

The imfinzi (durvalumab) market covered in this report is segmented –

1) By Type: 2.4mL Injection, 10mL Injection

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications

Imfinzi (durvalumab) Market Growth Trends Reshaping The Competitive Landscape

Major companies in the Global Imfinzi (durvalumab) market are concentrating on expanding indications, such as perioperative use combined with chemotherapy, to achieve a competitive advantage. As an illustration, in January 2023, AstraZeneca plc, a biopharmaceutical company from the UK, reported that IMFINZI alongside chemotherapy more than doubled the pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers when compared to chemotherapy alone. This approach incorporates a two-phase treatment (pre-surgery and post-surgery) and provides a sustained immune activation benefit. This move into gastrointestinal cancer settings emphasizes AstraZeneca’s objective to strengthen its clinical presence and encourage long-term product adoption. However, this strategy also carries regulatory risks, since more intricate treatment regimens demand additional trial data and health economic validation.

Imfinzi (durvalumab) Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.

View The Full Imfinzi (durvalumab) Market Report:

https://thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Imfinzi (durvalumab) Market Top Region: Where Does Most Revenue Come From?

North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Imfinzi (durvalumab) Market Growth From $ Billion In 2026 To $ Billion By 2030 At A CAGR Of %

The Imfinzi (durvalumab) market has experienced swift expansion within the past few years and is set to rise from $3.01 million in 2025 to $3.36 million in 2026, reflecting a compound annual growth rate (CAGR) of 11.4%. This historical growth was driven by factors including the clinical effectiveness of immune checkpoint inhibitors, an increase in lung cancer incidence, oncology-focused regulatory approvals, enhanced survival rates, and robust investment from pharmaceutical companies.

The anticipated expansion of the durvalumab (Imfinzi) market is projected to be swift over the coming years. By 2030, its value is forecast to reach $5.11 million, driven by an 11.1% compound annual growth rate (CAGR). This projected growth during the forecast period stems from several factors: the drug’s entry into new cancer indications, a rise in immunotherapy availability, an uptick in oncology clinical trials, higher healthcare spending on cancer treatments, and the creation of combination therapy protocols. Key developments shaping this period include the growing preference for PD-L1 inhibitors, the broader application of immunotherapy in lung cancer cases, an increase in combined immuno-oncology treatment plans, a heightened emphasis on biomarker-guided therapies, and the drug’s more extensive implementation across a range of solid tumors.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Imfinzi (durvalumab) Market Demand Drivers: What Is Fueling Industry Growth?

The anticipated increase in cancer cases is expected to fuel expansion in the Imfinzi (durvalumab) market moving forward. Cancer describes a set of illnesses involving abnormal cells that multiply and spread uncontrollably within the body, potentially infiltrating and damaging healthy tissue. This rising trend in cancer incidence is largely propelled by an aging demographic, since cancer risk elevates with advancing age, along with lifestyle influences like tobacco use, inadequate nutrition, and excess weight, which all contribute to increased cancer rates. Durvalumab, marketed as Imfinzi, functions in cancer treatment by blocking the PD-L1 protein, thereby hindering cancer cells from escaping immune system recognition. As an illustration, data from the National Cancer Institute (NIH), a U.S. government entity, indicated in May 2024 that there were 18.1 million cancer survivors in the United States in 2022, with projections showing an increase to 22.5 million by 2032. Consequently, the escalating frequency of cancer is propelling growth within the Imfinzi (durvalumab) market.

The expansion of personalized medicine is anticipated to drive growth in the Imfinzi (durvalumab) market looking ahead. Personalized medicine represents a healthcare approach that customizes treatment and medical strategies based on each patient’s unique attributes, including genetic factors, lifestyle, and environment, with the goal of delivering the most effective and accurate results. The increasing adoption of personalized medicine stems from developments in genomic technologies, a deeper comprehension of molecular biology, wider accessibility to precise diagnostic instruments, and a push for targeted therapies that boost patient outcomes while reducing adverse effects. Imfinzi (durvalumab) supports personalized medicine through its action of targeting and blocking the PD-L1 protein, allowing customized immunotherapy approaches for cancer patients that are adapted to specific tumor biology and immune system profiles, thereby improving treatment success and limiting unnecessary side effects. For example, as reported by the Personalized Medicine Coalition, a representative U.S. organization, in 2023, the FDA approved personalized treatments for 34% of new drugs in 2022, and over the prior eight years, these therapies received approval for at least 25% of new medications. Hence, the increasing adoption of personalized medicine is driving the Imfinzi (durvalumab) market forward.

Imfinzi (durvalumab) Market Segment Performance And Strategic Opportunities

The imfinzi (durvalumab) market covered in this report is segmented –

1) By Type: 2.4mL Injection, 10mL Injection

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications

Imfinzi (durvalumab) Market Innovation Trends: Which Developments Are Transforming The Industry?

Key players in the Global Imfinzi (durvalumab) market are concentrating on extending its approved uses, especially perioperative application alongside chemotherapy, to secure a market edge. As an example, in January 2023, AstraZeneca plc, a biopharmaceutical firm headquartered in the UK, revealed that IMFINZI combined with chemotherapy achieved more than double the pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers compared to chemotherapy alone. This approach includes a two-phase treatment before and after surgery, along with sustained immune activation advantages. Such expansion into gastrointestinal cancer indications highlights AstraZeneca’s effort to strengthen its clinical presence and foster sustained demand growth. Nevertheless, this approach carries regulatory challenges, given that the more intricate treatment protocols demand supplementary trial evidence and health economic verification.

Imfinzi (durvalumab) Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.

Access The Complete Imfinzi (durvalumab) Market Report:

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Imfinzi (durvalumab) Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Imfinzi (durvalumab) Market From 2026 To 2030?

The imfinzi (durvalumab) market size has expanded considerably in recent years. It is projected to grow from $3.01 million in 2025 to $3.36 million in 2026, exhibiting a compound annual growth rate (CAGR) of 11.4%. This historical growth can be linked to the clinical achievements of immune checkpoint inhibitors, the increasing prevalence of lung cancer, various regulatory approvals within oncology, improved patient survival outcomes, and robust pharmaceutical investment.

The Imfinzi (durvalumab) market size is projected to undergo rapid expansion in the upcoming years, with an anticipated increase to **$5.11 million in 2030, demonstrating a compound annual growth rate (CAGR) of 11.1%.** This growth within the forecast period is attributable to several factors, including its expansion into new cancer indications, enhanced accessibility to immunotherapy, an increase in oncology clinical trials, rising healthcare spending in oncology, and the development of combination treatment protocols. Significant trends expected during this period involve the growing adoption of PD-L1 inhibitors, the broader application of immunotherapy in lung cancer, the emergence of combination immuno-oncology regimens, a heightened focus on biomarker-driven therapies, and its expanded use across multiple solid tumors.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp

What Influential Factors Are Boosting The Imfinzi (durvalumab) Market Demand?

The rising occurrence of cancer is projected to fuel the expansion of the Imfinzi (durvalumab) market in the future. Cancer encompasses a range of illnesses marked by the unregulated proliferation and dissemination of atypical cells throughout the body, capable of infiltrating and damaging healthy tissues. The increasing prevalence of cancer is primarily attributable to an aging demographic, given that cancer risk escalates with age, alongside lifestyle elements such as tobacco use, poor nutrition, and excessive weight, all of which contribute to elevated cancer rates. Imfinzi (durvalumab) addresses cancer by impeding the PD-L1 protein, thereby hindering cancer cells from bypassing detection by the immune system. As an illustration, in May 2024, the National Cancer Institute (NIH), a U.S. government entity, reported that the U.S. had 18.1 million cancer survivors in 2022, a number anticipated to climb to 22.5 million by 2032. Consequently, the increasing incidence of cancer is propelling the growth of the Imfinzi (durvalumab) market.

How Does Segment Analysis Break Down The Imfinzi (durvalumab) Market Structure?

The imfinzi (durvalumab) market covered in this report is segmented –

1) By Type: 2.4mL Injection, 10mL Injection

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications

What Trends Are Influencing The Imfinzi (durvalumab) Market?

Major companies operating in the Global Imfinzi (durvalumab) market are emphasizing indication expansion, such as its use in perioperative settings in combination with chemotherapy, to achieve a competitive advantage. For instance, in January 2023, AstraZeneca plc, a UK-based biopharmaceutical company, announced that IMFINZI along with chemotherapy more than doubled the pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers when compared to chemotherapy alone, involving a two-phase treatment (pre-surgery and post-surgery) and delivering a sustained immune activation benefit. This move into gastrointestinal cancer treatment areas highlights AstraZeneca’s strategy to broaden its clinical presence and drive long-term product adoption. However, this approach also introduces regulatory risks, as the more complex treatment regimens demand additional trial data and health economic validation.

Who Are The Firms Contributing To The Imfinzi (durvalumab) Market Ecosystem?

Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.

Access The Complete Imfinzi (durvalumab) Market Report:

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report

Which Geographic Region Represents The Largest Imfinzi (durvalumab) Market Share?

North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Imfinzi (durvalumab) Market During The Forecast Period 2026–2030?

The imfinzi (durvalumab) market size has seen rapid expansion in recent years. It is projected to increase from $3.01 million in 2025 to $3.36 million in 2026, achieving a compound annual growth rate (CAGR) of 11.4%. The historical growth in this market can be attributed to the clinical success of immune checkpoint inhibitors, rising lung cancer prevalence, regulatory approvals in oncology, improved survival outcomes, and strong pharmaceutical investment.

The market size for imfinzi (durvalumab) is projected to undergo rapid expansion in the coming years. It is expected to reach $5.11 million by 2030, demonstrating a compound annual growth rate (CAGR) of 11.1%. This growth throughout the forecast period can be attributed to several factors including its expansion into new cancer indications, improved accessibility of immunotherapy, an increase in oncology clinical trials, rising healthcare spending in oncology, and the development of combination treatment protocols. Significant trends for the forecast period include the increasing adoption of PD-L1 inhibitors, the broadening application of immunotherapy in lung cancer, the proliferation of combination immuno-oncology regimens, a heightened focus on biomarker-driven therapies, and its more widespread use across multiple solid tumors.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp

Which Major Factors Are Driving The Expansion Of The Imfinzi (durvalumab) Market?

The increasing incidence of cancer is projected to stimulate the expansion of the Imfinzi (durvalumab) market. Cancer refers to a collection of illnesses typified by the unchecked proliferation and dissemination of atypical cells throughout the body, which can invade and devastate normal tissues. This rise in cancer cases is largely attributed to an aging populace, as susceptibility to cancer increases with age, and to lifestyle aspects such as smoking, poor dietary habits, and obesity, which foster higher rates of the disease. Durvalumab (Imfinzi) operates against cancer by blocking the PD-L1 protein, preventing malignant cells from avoiding detection by the immune system. As an illustration, the National Cancer Institute (NIH), a US-based government agency, reported in May 2024 that the U.S. had 18.1 million cancer survivors in 2022, a number projected to grow to 22.5 million by 2032. Thus, the heightened incidence of cancer is propelling the growth of the Imfinzi (durvalumab) market.

What Market Segments Are Evaluated Within The Imfinzi (durvalumab) Market?

The imfinzi (durvalumab) market covered in this report is segmented –

1) By Type: 2.4mL Injection, 10mL Injection

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications

What Industry Trends Are Redefining The Imfinzi (durvalumab) Market?

Leading firms within the Global Imfinzi (durvalumab) market are prioritizing the expansion of its approved indications, including its application in perioperative settings alongside chemotherapy, to secure a competitive edge. As an example, in January 2023, AstraZeneca plc, a biopharmaceutical company headquartered in the UK, disclosed that the combination of IMFINZI and chemotherapy significantly elevated the pathologic complete response rate, more than doubling it in early-stage resectable gastric and gastroesophageal junction cancers compared to chemotherapy by itself. This treatment involves two phases (before and after surgery) and offers a lasting benefit in immune activation. This expansion into treating gastrointestinal cancers highlights AstraZeneca’s strategic approach to enhance its clinical presence and foster sustained product adoption over time. Nevertheless, this approach also introduces regulatory challenges, given that more intricate treatment protocols necessitate further clinical trial data and validation from a health economic perspective.

Who Are The Top Market Participants Influencing The Imfinzi (durvalumab) Market?

Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.

Read the full imfinzi (durvalumab) market report here:

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report

Which Region Currently Holds The Largest Share Of The Imfinzi (durvalumab) Market?

North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Imfinzi (durvalumab) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19906&type=smp

Browse Through More Reports Similar to the Global Imfinzi (durvalumab) Market 2026, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Imfinzi (durvalumab) Market During The Forecast Period 2026–2030?

The imfinzi (durvalumab) market size has seen rapid expansion in recent years. It is projected to increase from $3.01 million in 2025 to $3.36 million in 2026, achieving a compound annual growth rate (CAGR) of 11.4%. The historical growth in this market can be attributed to the clinical success of immune checkpoint inhibitors, rising lung cancer prevalence, regulatory approvals in oncology, improved survival outcomes, and strong pharmaceutical investment.

The market size for imfinzi (durvalumab) is projected to undergo rapid expansion in the coming years. It is expected to reach $5.11 million by 2030, demonstrating a compound annual growth rate (CAGR) of 11.1%. This growth throughout the forecast period can be attributed to several factors including its expansion into new cancer indications, improved accessibility of immunotherapy, an increase in oncology clinical trials, rising healthcare spending in oncology, and the development of combination treatment protocols. Significant trends for the forecast period include the increasing adoption of PD-L1 inhibitors, the broadening application of immunotherapy in lung cancer, the proliferation of combination immuno-oncology regimens, a heightened focus on biomarker-driven therapies, and its more widespread use across multiple solid tumors.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp

Which Major Factors Are Driving The Expansion Of The Imfinzi (durvalumab) Market?

The increasing incidence of cancer is projected to stimulate the expansion of the Imfinzi (durvalumab) market. Cancer refers to a collection of illnesses typified by the unchecked proliferation and dissemination of atypical cells throughout the body, which can invade and devastate normal tissues. This rise in cancer cases is largely attributed to an aging populace, as susceptibility to cancer increases with age, and to lifestyle aspects such as smoking, poor dietary habits, and obesity, which foster higher rates of the disease. Durvalumab (Imfinzi) operates against cancer by blocking the PD-L1 protein, preventing malignant cells from avoiding detection by the immune system. As an illustration, the National Cancer Institute (NIH), a US-based government agency, reported in May 2024 that the U.S. had 18.1 million cancer survivors in 2022, a number projected to grow to 22.5 million by 2032. Thus, the heightened incidence of cancer is propelling the growth of the Imfinzi (durvalumab) market.

What Market Segments Are Evaluated Within The Imfinzi (durvalumab) Market?

The imfinzi (durvalumab) market covered in this report is segmented –

1) By Type: 2.4mL Injection, 10mL Injection

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications

What Industry Trends Are Redefining The Imfinzi (durvalumab) Market?

Leading firms within the Global Imfinzi (durvalumab) market are prioritizing the expansion of its approved indications, including its application in perioperative settings alongside chemotherapy, to secure a competitive edge. As an example, in January 2023, AstraZeneca plc, a biopharmaceutical company headquartered in the UK, disclosed that the combination of IMFINZI and chemotherapy significantly elevated the pathologic complete response rate, more than doubling it in early-stage resectable gastric and gastroesophageal junction cancers compared to chemotherapy by itself. This treatment involves two phases (before and after surgery) and offers a lasting benefit in immune activation. This expansion into treating gastrointestinal cancers highlights AstraZeneca’s strategic approach to enhance its clinical presence and foster sustained product adoption over time. Nevertheless, this approach also introduces regulatory challenges, given that more intricate treatment protocols necessitate further clinical trial data and validation from a health economic perspective.

Who Are The Top Market Participants Influencing The Imfinzi (durvalumab) Market?

Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.

Read the full imfinzi (durvalumab) market report here:

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report

Which Region Currently Holds The Largest Share Of The Imfinzi (durvalumab) Market?

North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Imfinzi (durvalumab) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19906&type=smp

Browse Through More Reports Similar to the Global Imfinzi (durvalumab) Market 2026, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the imfinzi (durvalumab) market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Imfinzi (durvalumab) Market in 2026, and what figure is it projected to hit by 2030?

The imfinzi (durvalumab) market size has experienced rapid expansion over recent years. It is anticipated to expand from $3.01 million in 2025 to $3.36 million in 2026, achieving a compound annual growth rate (CAGR) of 11.4%. The upward trend observed historically can be credited to the clinical achievements of immune checkpoint inhibitors, the increasing prevalence of lung cancer, approvals from regulatory bodies in oncology, enhanced survival outcomes, and robust pharmaceutical investment.

The market for imfinzi (durvalumab) is projected to experience substantial growth over the coming years. This market is anticipated to reach $5.11 million by 2030, exhibiting a compound annual growth rate (CAGR) of 11.1%. Factors contributing to this growth during the forecast period include the broadening of its use into new cancer indications, improved access to immunotherapy, an increase in oncology clinical trials, greater healthcare spending on oncology, and the creation of new combination treatment protocols. Key trends expected during this period involve the increasing uptake of PD-L1 inhibitors, the wider application of immunotherapy in lung cancer, the development of more combination immuno-oncology regimens, a heightened emphasis on biomarker-guided therapies, and its expanded application across various solid tumors.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp

Which Drivers Are Affecting Market Participation In The Imfinzi (durvalumab) Market?

The increasing prevalence of cancer is anticipated to fuel the expansion of the Imfinzi (durvalumab) market moving forward. Cancer encompasses a range of illnesses marked by the uncontrolled multiplication and dispersion of abnormal cells throughout the body, capable of invading and destroying healthy tissues. This rise in cancer cases is largely attributed to an aging global population, as cancer risk escalates with age, alongside lifestyle elements such as smoking, inadequate diet, and obesity, all contributing to higher cancer rates. Durvalumab (Imfinzi) functions as a cancer treatment by inhibiting the PD-L1 protein, thereby preventing cancer cells from avoiding detection by the immune system. For example, data from May 2024 by the National Cancer Institute (NIH), a US-based government agency, indicated that in 2022, there were 18.1 million cancer survivors in the U.S., a figure projected to increase to 22.5 million by 2032. Consequently, the rising incidence of cancer is a key driver for the growth of the Imfinzi (durvalumab) market. Imfinzi (durvalumab) Market Driver: The Rise Of Personalized Medicine Fueling Growth In The Imfinzi (durvalumab) Market

What Segment Categories Are Covered In The Imfinzi (durvalumab) Market?

The imfinzi (durvalumab) market covered in this report is segmented –

1) By Type: 2.4mL Injection, 10mL Injection

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications

Which Competitive Trends Are Impacting The Structure Of The Imfinzi (durvalumab) Market?

Key companies active in the Global Imfinzi (durvalumab) market are prioritizing the expansion of indications, such as perioperative use combined with chemotherapy, to enhance their competitive standing. For example, in January 2023, AstraZeneca plc, a UK based biopharmaceutical company, revealed that IMFINZI plus chemotherapy more than doubled the pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers compared to chemotherapy alone. This regimen involved a two-phase treatment (pre surgery and post surgery) and exhibited a lasting immune activation benefit. This move into gastrointestinal cancer treatments highlights AstraZeneca’s approach to expand its clinical presence and foster enduring product uptake. Nonetheless, this strategy also introduces regulatory challenges, as these more elaborate treatment plans demand supplementary trial data and health economic validation.

Which Leading Companies Dominate The Imfinzi (durvalumab) Market Share?

Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report

How Does The Imfinzi (durvalumab) Market Perform Across Major Global Regions?

North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Imfinzi (durvalumab) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19906&type=smp

Browse Through More Reports Similar to the Global Imfinzi (durvalumab) Market 2026, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Imfinzi (durvalumab) Market Size Shifted, And What Is the Outlook Through 2034?

The market size of Imfinzi (durvalumab) has experienced accelerated growth recently. Projection suggests that its worth will escalate from $2,701.22 million in 2024 to $3,013.33 million in 2025, reflecting a compound annual growth rate (CAGR) of 11.6%. The growth that the historical period has witnessed can be linked to several factors such as broadened indications and approvals, the increasing preference for targeted therapies, a surge in patient interest in personalized treatments, advancements in immunotherapy, and a heightened demand for immunotherapies among patients.

How Much Will the Imfinzi (durvalumab) Market Be Worth in 2029?

Anticipated to experience a rapid increase in the coming years, the market size for imfinzi (durvalumab) is projected to reach $4,143.36 million by 2029, with a compound annual growth rate (CAGR) of 11.3%. This growth during the forecast period is credited to the escalating use of combined therapies, an uptick in pharmaceutical research and development, a surge in cancer rates, wider acceptance of immunotherapy, an expanding regulatory context, and increased investments in healthcare facilities. Significant trends during this forecast period encompass the embrace of personalized medicine methods, the drive towards individualized medicine, the uptake of biosimilars, the incorporation of artificial intelligence and machine learning, and partnerships among pharmaceutical companies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp

Which is the Largest Company in the Imfinzi (durvalumab) Market?

Major companies operating in the imfinzi (durvalumab) market include AstraZeneca PLC.

What Are the Main Market Drivers in the Imfinzi (durvalumab) Industry?

The increasing prevalence of cancer is anticipated to fuel the expansion of the Imfinzi (durvalumab) market in the future. Cancer is an umbrella term for a cluster of diseases marked by the unregulated multiplication and dissemination of anomalous cells in the body, which may infiltrate and demolish conventional tissues. This escalation in cancer cases is primarily due to an ageing demographic, as cancer risk heightens with age, along with lifestyle elements such as smoking, unhealthy eating habits, and obesity that escalate cancer rates. Durvalumab (Imfinzi) treats cancer by obstructing the PD-L1 protein, preventing the cancer cells from avoiding detection by the immune system. For example, the National Cancer Institute (NIH), a US-based governmental institution, reported in May 2024, that in 2022, there were 18.1 million cancer survivors in the U.S, estimated to surge to 22.5 million by 2032. Therefore, the increasing prevalence of cancer is fuelling the growth of the Imfinzi (durvalumab) market. The Surge In Personalized Medicine Boosts The Growth Of The Imfinzi (durvalumab) Market

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=19906&type=smp

How Is the Imfinzi (durvalumab) Market Segments Structured?

The imfinzi (durvalumab)market covered in this report is segmented –

1) By Type: 2.4mL Injection; 10mL Injection

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications

What Strategic Trends Are Transforming the Imfinzi (durvalumab) Market?

The primary trend in the Imfinzi (durvalumab) industry is focusing on acquiring regulatory approvals to broaden its application to more cancer forms, boost its clinical indications, and extend its market accessibility. Regulatory approvals are official permissions bestowed by health regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), enabling the marketing and application of a drug, medical device, or treatment in particular regions. For example, in September 2022, AstraZeneca, a pharmaceutical corporation based in the UK, achieved FDA approval for durvalumab (Imfinzi) to serve as a treatment for locally advanced or metastatic biliary tract cancer (BTC) in adults, founded on the findings of the TOPAZ-1 trial. This vital study revealed that when durvalumab was joined with gemcitabine and cisplatin, it notably boosted overall survival (12.8 months vs. 11.5 months for placebo) and progression-free survival (7.2 months vs. 5.7 months). The research involved 685 patients with varied forms of BTC, with common side effects including fatigue, nausea, and abdominal pain. The proposed dosage is 1,500 mg every three weeks during combined therapy, followed by monotherapy each four weeks.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report

Which Global Regions Offer the Highest Growth in the Imfinzi (durvalumab) Market?

North America was the largest region in the imfinzi (durvalumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19906

This Report Delivers Insight On:

1. How big is the imfinzi (durvalumab) market, and how is it changing globally?

2. Who are the major companies in the imfinzi (durvalumab) market, and how are they performing?

3. What are the key opportunities and risks in the imfinzi (durvalumab) market right now?

4. Which products or customer segments are growing the most in the imfinzi (durvalumab) market?

5. What factors are helping or slowing down the growth of the imfinzi (durvalumab) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the imfinzi (durvalumab) global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Imfinzi (durvalumab) Market Size Shifted, And What Is the Outlook Through 2034?

In recent years, the market size for imfinzi (durvalumab) has seen speedy expansion. It is projected to increase from $2,701.22 million in 2024 to $3,013.33 million in 2025, marking a compound annual growth rate (CAGR) of 11.6%. This marked rise during the historical period can be traced to expansions in indications and approvals, the surge in demand for targeted treatments, an upward trend in patient preference for personalized treatments, advancements in immunotherapy, and heightened patient demand for immunotherapies.

Expectations are high for significant growth in the Imfinzi (Durvalumab) market in the coming years, with a projected value of $4,143.36 million in 2029 from a compound annual growth rate (CAGR) of 11.3%. This predicted expansion during the forecasted period is linked to multiple factors including the increasing use of combination therapies, the escalation in pharmaceutical research and development, the rising incidence of cancer, the growing acceptance of immunotherapy, expanding regulatory footprint, and heightened investment in healthcare facilities. Further influencing this forecasted growth are major trends including the implementation of personalized medicine techniques, a shift towards individualized medicine, the embracing of biosimilars, the integration of revolutionary AI and machine learning technologies and strategic collaborations between pharmaceutical companies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Imfinzi (durvalumab) Market?

The increasing cases of cancer are anticipated to fuel the Imfinzi (durvalumab) market. Disease such as cancer is characterized by uncontrolled cell overgrowth and spreading destructive to the normal body tissues. Spurring cases of cancer is largely attributed to aging, as cancer risk correlates with age, alongside lifestyle choices such as habitual smoking, unhealthy diet and obesity that heighten the probability of cancer. Imfinzi (durvalumab) works in treating cancer by impeding the PD-L1 protein which helps cancer cells avoid the immune system’s detection. As per the data by the National Cancer Institute (NIH), a US government organization, as of 2024, the number of cancer survivors in the U.S. in 2022 were 18.1 million and this figures are projected to increase to 22.5 million by 2032. Hence, the escalating rates of cancer bolster the expansion of the Imfinzi (durvalumab) market. The Upturn of Personalized Medicine Giving Rise to the Imfinzi (durvalumab) Market

Which Primary Segments of the Imfinzi (durvalumab) Market Are Driving Growth and Industry Transformations?

The imfinzi (durvalumab)market covered in this report is segmented –

1) By Type: 2.4mL Injection; 10mL Injection

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19906&type=smp

Which Regions Are Key Players in the Growth of the Imfinzi (durvalumab) Market?

North America was the largest region in the imfinzi (durvalumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Imfinzi (durvalumab) Market?

The imfinzi (durvalumab) market is majorly influenced by a trend that involves gaining government health agencies’ approvals to widen its use for various cancer types, enhance its clinical implications, and boost its market presence. Such regulatory approvals are officially issued by health authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), allowing the marketing and utilization of a specific medical product in certain regions. For example, AstraZeneca, an established pharmaceutical company from the UK, secured the FDA’s approval for durvalumab (Imfinzi) as a treatment for localized or metastatic biliary tract cancer (BTC) in adults in September 2022. The approval was based on the results from the crucial TOPAZ-1 study. This study showed that durvalumab, when used with gemcitabine and cisplatin, considerably enhanced patients’ overall survival (12.8 months against 11.5 months for placebo) and progression-free survival (7.2 months against 5.7 months). The research enrolled 685 patients afflicted with different BTC forms, with fatigue, nausea, and abdominal pain being common side effects. Durvalumab’s recommended dosage is 1,500 mg every three weeks during the combination therapy, followed by a monotherapy every four weeks.

View the full report here:

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report

What Parameters Are Used to Define the Imfinzi (durvalumab) Market?

Imfinzi (durvalumab) is a human monoclonal antibody and an immunotherapy drug specifically designed to block programmed death-ligand 1 (PD-L1), a protein that tumors use to evade detection by the immune system. It is used to treat various cancers, including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, and advanced urothelial carcinoma.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19906

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Imfinzi (durvalumab) Market?

The Imfinzi (durvalumab) market’s expansion is anticipated due to the increasing prevalence of cancer. Cancer, a collection of diseases characterized by unchecked abnormal cell growth and spread, can lead to the destruction of healthy tissues. The uptick in cancer cases is attributed largely to an aging population and lifestyle choices like smoking, unhealthy diet, and obesity, which are known to increase cancer risks. Imfinzi (durvalumab) plays a crucial role in cancer treatment by blocking the PD-L1 protein, hindering the ability of cancer cells to escape immune system detection. An example of this growing need is seen in the data from the National Cancer Institute (NIH), a US-based government agency, which indicated that 18.1 million cancer survivors were recorded in the U.S in 2022, a figure projected to rise to 22.5 million by 2032. Therefore, this rise in cancer incidence is propelling the Imfinzi (durvalumab) market. Additionally, the burgeoning field of personalized medicine is augmenting the Imfinzi (durvalumab) market growth. Personalized medicine represents a shift in the healthcare approach, focusing on optimizing treatments and healthcare strategies based on each patient’s unique genetics, environment, and lifestyle. This trend is being driven by advances in genomics, increased knowledge of molecular biology, the availability of precision diagnostic tools, and a rising demand for targeted therapies that optimize patient outcomes with minimal side effects. By specifically targeting and inhibiting the PD-L1 protein, Imfinzi (durvalumab) fits within personalized medicine by allowing for tailored cancer immunotherapy treatments that rely on individual tumor biology and immune characteristics, thereby bolstering treatment effectiveness and reducing unwarranted side effects. The Personalized Medicine Coalition, a US-based representative organization, reported in 2023 that the FDA approved personalized medicines for 34% of new drugs in 2022, and at least 25% of new drugs in the previous eight years. Consequently, the mounting interest in personalized medicine is fueling the Imfinzi (durvalumab) market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp

#What Long-Term Growth Rate is Expected for theImfinzi (durvalumab) Market Between 2025 and 2034?

The imfinzi (durvalumab) market has rapidly grown in recent years. It will rise from $2,701.22 million in 2024 to $3,013.33 million in 2025, reflecting an 11.6% CAGR. This has been driven by expanded approvals, growing demand for precision therapies, advances in immunotherapy, and a patient shift toward personalized treatments.

The Imfinzi (durvalumab) market is set to grow rapidly, projected to reach $4,143.36 million in 2029 at a CAGR of 11.3%. Growth will stem from rising use of combination therapies, increasing R&D, cancer prevalence, immunotherapy adoption, regulatory expansion, and healthcare infrastructure investment. Leading trends include a focus on tailored treatments, AI/ML integration, biosimilar acceptance, and pharma collaborations.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19906

What Are the Most Significant Market Trends Transforming theImfinzi (durvalumab) Market?

The imfinzi (durvalumab) market’s primary trend is about securing necessary regulatory approvals to broaden its applicability for additional types of cancer, enhance clinical indications and broaden its market scope. Regulatory approvals mean the official permission that health regulatory bodies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), confer for marketing and using a certain drug, medical device or treatment in specific regions. As an example, AstraZeneca, a pharmaceutical company based in the UK, gained FDA approval in September 2022 to use durvalumab (Imfinzi) in treating locally advanced or metastatic biliary tract cancer (BTC) in adults, founded on the outcomes of the TOPAZ-1 trial. The groundbreaking study showcased that durvalumab, in combination with gemcitabine and cisplatin, considerably enhanced overall survival rates (12.8 months vs. 11.5 months for placebo) and progression-free survival (7.2 months vs. 5.7 months). The study included 685 patients with different BTC forms, with common side effects being fatigue, nausea, and abdominal pain. The suggested dosage is 1,500 mg every three weeks during combination therapy and then monotherapy every four weeks.,

What Are the Top Market Players Propelling the Growth of theImfinzi (durvalumab) Industry?

Major companies operating in the imfinzi (durvalumab) market include AstraZeneca PLC.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report

Which Primary Segments of the Imfinzi (durvalumab) Market Are Driving Growth and Industry Transformations?

The imfinzi (durvalumab)market covered in this report is segmented –

1) By Type: 2.4mL Injection; 10mL Injection

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=19906&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Imfinzi (durvalumab) Market?# Market?

North America was the largest region in the imfinzi (durvalumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Imfinzi (durvalumab) Market 2025, By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

mRNA Cancer Vaccines And Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mrna-cancer-vaccines-and-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the imfinzi (durvalumab) market?

Over the past few years, the market for imfinzi (durvalumab) has seen substantial growth. Anticipated to expand from $2,701.22 million in 2024 to $3,013.33 million in 2025, it boasts a compound annual growth rate (CAGR) of 11.6%. Factors such as increased indications and approvals, the rising demand for targeted and personalized therapies, enhancements in immunotherapy, and an upward trend in patient interest for immunotherapies are all responsible for the growth witnessed in the historic period.

What will be the imfinzi (durvalumab) market size in the future?

Expectations are that the market size for imfinzi (durvalumab) will experience significant growth in the coming years. The forecast suggests that it will increase to $4,143.36 million by 2029, exhibiting a compound annual growth rate (CAGR) of 11.3%. Factors contributing to this anticipated growth during the forecast period include increased use of combined treatments, enhanced pharmaceutical research and development, an escalating occurrence of cancer, a surge in the acceptance of immunotherapy, expanding regulatory influence, and heightened investment in healthcare facilities. Major future trends incorporate the utilization of tailored medicine techniques, emphasis on personalized medicine, adoption of biosimilars, integration of artificial intelligence and machine learning technologies, and partnerships within the pharmaceutical industry.

Get your imfinzi (durvalumab) market report here!

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report

What main drivers are fueling expansion in the imfinzi (durvalumab) market?

An increase in cancer occurrences is anticipated to propel the development of the Imfinzi (durvalumab) market in the future. Cancer is a group of diseases marked by the uncontained development and dissemination of unhealthy cells in the human body, capable of invading and obliterating normal tissue. Cancer’s increasing prevalence can be attributed majorly to an aging demographic as the possibility of cancer enhances with age and lifestyle variables such as smoking, improper diet, and obesity that add to heightened cancer rates. The drug durvalumab (Imfinzi) impedes the PD-L1 protein, thereby preventing cancer cells from escaping the immune system’s detection. As an illustration, the National Cancer Institute in May 2024 reported that in 2022 the U.S. had 18.1 million cancer survivors, and this number is projected to reach 22.5 million by 2032. This surge in cancer incidences is aiding the Imfinzi (durvalumab) market’s expansion. An upward trend in personalized medicine is set to further stimulate the growth of the Imfinzi (durvalumab) market. Personalized medicine refers to a medical model that adapts treatment and healthcare plans to the specific attributes of each patient including their gene pattern, surroundings, and lifestyle. The burgeoning precedent of personalized medicine can be attributed to progress in genomic technology, enhanced understanding of molecular biology, the extending availability of diagnostic instruments with precision, and the appeal for targeted therapies that optimize patient outcomes while reducing adverse effects. Imfinzi (durvalumab) bolsters personalized medicine by facilitating custom immunotherapy treatments for cancer sufferers rooted in particular tumor biology and immune system features, consequently augmenting treatment potency and eliminating needless side effects. According to the Personalized Medicine Coalition in 2023, the FDA sanctioned personalized medicine for 34% of emerging drugs in 2022, and in the previous eight years, they had been sanctioned for a minimum of 25% of novel drugs. Hence, the rise of personalized medicine propels the Imfinzi (durvalumab) market.

What key areas define the segmentation of the global imfinzi (durvalumab) market?

The imfinzi (durvalumab)market covered in this report is segmented –

1) By Type: 2.4mL Injection; 10mL Injection

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp

Who are the dominant players expanding their reach in the imfinzi (durvalumab) market?

Major companies operating in the imfinzi (durvalumab) market include AstraZeneca PLC.

How are evolving market trends shaping imfinzi (durvalumab) Strategies?

The primary trend in the imfinzi (durvalumab) market involves efforts to secure regulatory clearances with the aim of extending its use for more cancer forms, broadening its clinical applications, and enlarging its market footprint. These regulatory consents are formal permissions given by governmental health bodies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), which allow a medication, medical device, or treatment to be sold and applied in specific areas. For example, AstraZeneca, a pharmaceutical firm based in the UK, gained FDA clearance for durvalumab (Imfinzi) in September 2022 for treating locally progressed or metastatic biliary tract cancer (BTC) in adults. This was based on the TOPAZ-1 trial results, a landmark study showing that durvalumab, when used with gemcitabine and cisplatin, meaningfully boosted overall survival (12.8 months compared to 11.5 months for placebo) and progression-free survival (7.2 months compared to 5.7 months). The study was comprised of 685 patients with different types of BTC, with commonly reported side effects like fatigue, nausea, and abdominal pain. The suggested dose is 1,500 mg every three weeks during combined treatment, followed by once every four weeks as a standalone therapy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19906

Which regions are emerging as leaders in the imfinzi (durvalumab) market?

North America was the largest region in the imfinzi (durvalumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

mRNA Cancer Vaccines And Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mrna-cancer-vaccines-and-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: